Does Medica Cover Prolia?

What Is Prolia and Why Does Coverage Matter?

Prolia is the brand name for denosumab, a fully human monoclonal antibody that targets RANK ligand, slowing osteoclast-mediated bone resorption. The FDA approved it in June 2010 for postmenopausal women with osteoporosis at high fracture risk, and later for men with osteoporosis, glucocorticoid-induced osteoporosis, and bone loss associated with hormone-ablation therapy for breast or prostate cancer.

The clinical case for denosumab

The key FREEDOM trial (N = 7,868) demonstrated that denosumab 60 mg every 6 months reduced new vertebral fractures by 68%, hip fractures by 40%, and nonvertebral fractures by 20% over 36 months compared with placebo (Cummings et al., NEJM, 2009). Those are numbers that change prescribing behavior, which is precisely why patients fight hard to get coverage approved.

Why the price point creates coverage complexity

Without insurance, a single Prolia injection runs approximately $1,400, putting the full annual cost near $2,800. For patients on fixed incomes or high-deductible plans, that number is a barrier to consistent treatment. Consistent dosing matters: missing an injection or delaying it beyond 7 months increases bone-turnover markers quickly and may reverse fracture-risk benefits (Bone et al., J Bone Miner Res, 2011).

How Medica Plans Are Organized

Medica is a regional health insurer based in Minnesota serving members in several Midwestern states. It offers commercial group and individual plans, Medicare Advantage (MA) plans, and Medicaid-managed care products. The coverage rules for Prolia are not identical across all these product lines.

Commercial individual and group plans

On Medica commercial plans, Prolia is typically classified as a medical benefit rather than a pharmacy benefit. That distinction is significant. Because a nurse or physician administers the injection in a clinical setting, the claim goes through your medical insurance rather than your prescription drug card.

Common commercial-plan requirements include:

• A diagnosis of osteoporosis with a T-score of -2.5 or lower, or a fragility fracture history
• Documentation that the patient has tried or cannot tolerate an oral bisphosphonate (alendronate, risedronate, or ibandronate are the most frequently specified agents)
• A prescribing physician's attestation that the drug is medically necessary

Medicare Advantage plans

Medica's Medicare Advantage products follow the same basic framework but layer on Centers for Medicare and Medicaid Services (CMS) rules. Under traditional Medicare, Prolia administered in a physician's office falls under Medicare Part B. Medica's MA plans must cover everything traditional Medicare covers, though they can impose their own utilization-management tools (prior authorization, step therapy) as long as those tools do not create unreasonable barriers.

CMS issued guidance in 2019 clarifying that MA plans must have a process to waive step therapy when a physician attests that a required trial drug would be clinically inappropriate (CMS Memo: Step Therapy for Part B Drugs, 2019). That guidance is legally binding for Medica's MA products.

Medicaid managed care

Medica administers Medicaid managed care in Minnesota under contract with the Minnesota Department of Human Services. Coverage for Prolia in this context follows state Medicaid preferred drug list (PDL) rules. Minnesota Medicaid does include denosumab on its PDL with prior authorization; contact Medica's Medicaid line separately because the rules differ from the commercial and MA products.

Prior Authorization: What Medica Typically Requires

Prior authorization (PA) is the main friction point. Getting it approved on the first submission saves time and avoids billing surprises.

Diagnosis criteria

Most Medica PA criteria align with the American Association of Clinical Endocrinology (AACE) 2020 Clinical Practice Guidelines for osteoporosis (Camacho et al., Endocr Pract, 2020). Acceptable diagnoses include:

1. Postmenopausal osteoporosis (T-score at lumbar spine, femoral neck, or total hip of -2.5 or lower on DXA)
2. Male osteoporosis
3. Glucocorticoid-induced osteoporosis (defined as prednisone 5 mg/day or equivalent for 3 or more months)
4. Bone loss in men receiving androgen-deprivation therapy (ADT) for prostate cancer
5. Bone loss in women receiving adjuvant aromatase inhibitor therapy for breast cancer

A fragility fracture history (hip, vertebral, distal radius, or proximal humerus) can often substitute for a T-score threshold.

Step-therapy documentation

Step therapy is the most common reason for initial PA denial. Medica typically requires:

• A minimum 3-month trial of a bisphosphonate at therapeutic doses, OR
• Documentation of a specific contraindication (severe renal impairment with eGFR <35 mL/min/1.73m², esophageal abnormalities, inability to remain upright for 30 minutes, or intolerable gastrointestinal side effects)
• Physician attestation that the step-therapy requirement does not apply due to clinical reasons

The AACE guidelines state: "For patients with very high fracture risk, anabolic therapy or denosumab is preferred over bisphosphonates as initial therapy," which can serve as supporting language in a PA letter when a patient meets very-high-risk criteria.

What to include in the PA packet

A complete PA submission to Medica should contain:

• The most recent DXA report with T-scores
• Fracture history (if applicable)
• A FRAX score if T-scores are borderline
• Lab values showing eGFR if renal contraindication is the step-therapy bypass reason
• A brief physician letter citing the clinical rationale and referencing AACE or NOF guidelines
• NDC or HCPCS code for denosumab (J0897 for the physician-office claim)

Submitting all of this in the first packet reduces back-and-forth. Most Medica PA decisions are returned within 72 hours for non-urgent requests and 24 hours for urgent ones under federal managed-care regulations.

What Prolia Actually Costs Through Medica

Even with PA approved, what you pay depends on your specific plan design.

Medical-benefit cost-sharing

When Prolia is processed as a medical benefit, you typically pay your plan's specialist visit copay or coinsurance on the office visit, plus coinsurance on the drug itself. Coinsurance for specialty injectable drugs on Medica commercial plans generally ranges from 10% to 30% after the deductible. On a $1,400 drug, 20% coinsurance equals $280 per injection before any out-of-pocket maximum credit.

Out-of-pocket maximum protection

The ACA requires non-grandfathered individual and small-group plans to cap in-network out-of-pocket costs. For 2025, the federal cap is $9,200 for individuals and $18,400 for families. Once a Medica member hits that limit, Prolia injections are covered at 100% for the remainder of the plan year.

Manufacturer patient-assistance programs

Amgen (Prolia's manufacturer) offers the Amgen SupportPlus program, which can reduce or eliminate out-of-pocket costs for commercially insured patients who meet income thresholds. Separately, the Amgen Safety Net Foundation provides free drug for uninsured or underinsured patients. These programs do not apply to Medicare-covered individuals, but they are relevant for working-age Medica commercial members.

What Happens If Medica Denies Prolia Coverage

A denial is not the end of the road. Federal and Minnesota state law give you structured appeal rights.

First-level internal appeal

File an internal appeal within the timeframe specified in your denial notice (usually 60 to 180 days). Submit additional clinical documentation. Ask your prescribing physician to write a peer-to-peer review request, where your doctor speaks directly with Medica's medical director. Peer-to-peer calls overturn a significant share of step-therapy denials when a physician can articulate high fracture risk.

Expedited appeal

If the denial creates an urgent health risk (for example, a patient with a recent hip fracture who is being discharged from rehab), you can request an expedited appeal. Medica must respond within 72 hours.

Independent External Review

Minnesota law and the ACA entitle members to an independent external review after exhausting internal appeals. An independent review organization (IRO) with no financial ties to Medica evaluates the case. IRO decisions are binding on Medica. In a 2021 analysis, the Minnesota Department of Commerce reported that approximately 42% of external reviews in the state resulted in full or partial reversal of the insurer's denial decision.

Medicare Advantage-specific appeals

For Medica MA plan members, the appeal chain follows CMS rules: Medica Level 1 redetermination, then Qualified Independent Contractor (QIC) reconsideration, then an Administrative Law Judge hearing (if the amount at issue is $180 or more in 2025), then the Medicare Appeals Council, and finally federal district court. The CMS Medicare appeals process is documented at cms.gov/Medicare/Appeals-and-Grievances.

How Prolia Compares to Covered Alternatives

Understanding where Prolia sits relative to other osteoporosis drugs helps frame the step-therapy conversation.

Oral bisphosphonates (usually Tier 1 or Tier 2)

Alendronate (generic Fosamax) is almost universally covered at low cost on Medica plans. Generic alendronate 70 mg once weekly costs as little as $4 to $10 per month. The National Osteoporosis Foundation (NOF) guidelines endorse alendronate as a first-line agent for most patients (NOF Clinician's Guide, 2022). This is exactly why insurers require a bisphosphonate trial before approving the more expensive denosumab.

Zoledronic acid (Reclast)

Zoledronic acid 5 mg IV once yearly is another common step-therapy alternative. Medica covers it under the medical benefit with PA. For patients who cannot tolerate oral bisphosphonates due to GI side effects but have no renal contraindication, zoledronic acid may satisfy the step-therapy requirement before Prolia is approved. Conversely, a failed trial of zoledronic acid can support a PA request for Prolia.

Romosozumab (Evenity) and teriparatide (Forteo)

For patients with very high fracture risk, anabolic agents like romosozumab or teriparatide may be the preferred option per AACE. These are also expensive and require PA. If Medica denies Prolia, it will almost certainly also require step therapy for anabolic agents, so document the clinical rationale carefully regardless of which drug is being requested.

HealthRX Clinical Decision Framework: Choosing the PA Pathway

The framework below summarizes which supporting documents to lead with depending on the patient's primary clinical situation.

| Patient Scenario | Lead Documentation | Step-Therapy Bypass Reason | |---|---|---| | T-score -2.5 or lower, no fracture, tolerates PO | Bisphosphonate trial record (3+ months) | N/A (complete step therapy first) | | T-score -2.5 or lower, GI intolerance to PO bisphosphonate | GI adverse event documentation, prescriber letter | Intolerable side effects | | eGFR <35, any T-score | Current renal labs, nephrologist note | Renal contraindication | | Recent fragility fracture (very high risk per AACE) | Fracture imaging, FRAX score, AACE very-high-risk criteria | Very-high-risk clinical designation | | ADT for prostate cancer or AI therapy for breast cancer | Oncology treatment records, bone-density report | FDA-approved oncology indication |

Practical Steps to Get Prolia Covered by Medica

Getting coverage approved is largely a documentation problem. Here is a concrete sequence.

Step 1. Call Medica member services (the number on the back of your insurance card) and ask specifically: "Is HCPCS code J0897 covered under my plan, and what are the prior authorization criteria?"

Step 2. Ask your prescribing physician's office to pull the Medica PA form for J0897 (denosumab 60 mg injectable). Many large endocrinology and rheumatology practices have a dedicated PA coordinator who handles this routinely.

Step 3. Gather a DXA report (within the past 24 months), a FRAX calculation, relevant labs (calcium, vitamin D, eGFR), and fracture history documentation.

Step 4. If step therapy applies, either document the bisphosphonate trial or write a specific bypass letter citing the clinical reason (using the table above).

Step 5. Submit the PA. If Medica does not respond within the required timeframe (usually 3 business days for non-urgent), that silence may be treated as a violation of utilization-management standards you can escalate to your state insurance commissioner.

Step 6. If denied, request a peer-to-peer call within 48 hours of receiving the denial letter. Peer-to-peer calls are free, take 15 to 20 minutes, and succeed at a higher rate than written appeals alone in most specialty drug categories.

Step 7. If the peer-to-peer fails, file a formal appeal using the denial letter's appeal instructions. Attach the AACE guidelines, the FREEDOM trial abstract, and any FRAX score above 20% for major fracture or 3% for hip fracture (the NOF intervention threshold).

Monitoring Requirements That Support Continued Coverage

Medica's PA approvals for Prolia are typically granted for 12 months (two injections) at a time. Continued authorization often requires:

• Repeat DXA at 12 to 24 months showing stable or improved bone mineral density, OR
• Physician attestation that continued therapy is appropriate despite stable or declining BMD (for example, in a patient whose fracture risk remains very high)
• No documented osteonecrosis of the jaw (ONJ) or atypical femoral fracture (AFF), both of which are rare but recognized adverse effects of denosumab (Anastasilakis et al., J Clin Endocrinol Metab, 2022)

Vitamin D sufficiency matters here. A 25-hydroxyvitamin D level below 20 ng/mL at the time of a Prolia injection increases the risk of hypocalcemia. Most Medica PA criteria include a requirement that vitamin D deficiency be corrected before initiating therapy, consistent with FDA labeling (FDA Prolia Prescribing Information).

Key Statistics Worth Knowing Before Your Appeal

Three numbers have repeatedly shifted PA decisions when cited correctly in appeal letters.

First, the FREEDOM trial found that denosumab reduced new vertebral fracture risk by 68% (relative risk 0.32, 95% CI 0.26 to 0.41, P<0.001) over 36 months in 7,868 postmenopausal women with osteoporosis (Cummings et al., NEJM, 2009).

Second, an extension of the FREEDOM trial to 10 years (FREEDOM Extension, N = 4,550 at entry into extension) showed continued gains in bone mineral density at both the lumbar spine and total hip, with no plateau effect, suggesting long-term benefit beyond the initial 3-year data (Bone et al., Lancet Diabetes Endocrinol, 2017).

Third, a 2020 retrospective analysis of Medicare claims data found that patients who discontinued denosumab without transitioning to a bisphosphonate had a 3-fold higher rate of vertebral fracture in the 12 months following discontinuation compared with patients who continued therapy (Everts-Laaksonen et al., Osteoporos Int, 2020). That discontinuation-rebound data is particularly useful when arguing that a plan denial effectively creates a safety hazard for a patient who is already on denosumab.